Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
10/01/2023 | Harpoon Therapeutics, Inc. | HARP | Grant | Common Stock | 3k | $0.00 | $0 | | 10/01/2023 |
07/01/2023 | Harpoon Therapeutics, Inc. | HARP | Grant | Common Stock | 18.7k | $0.00 | $0 | | 07/01/2023 |
06/15/2023 | Iterum Therapeutics plc | ITRM | Exercise | Restricted Share Units | 15.9k | $0.00 | $0 | | 06/15/2023 |
06/09/2023 | Disc Medicine, Inc. | | Grant | Stock Option (Right to Buy) | 7.1k | $45.69 | $326k | | 06/09/2023 |
04/01/2023 | Harpoon Therapeutics, Inc. | HARP | Grant | Common Stock | 18.3k | $0.00 | $0 | | 04/01/2023 |
12/29/2022 | Disc Medicine, Inc. | | Grant | Stock Option (Right to Buy) | 7k | $13.50 | $94.5k | | 12/29/2022 |
06/23/2022 | Iterum Therapeutics plc | ITRM | Exercise | Restricted Share Units | 36.8k | $0.00 | $0 | | 06/23/2022 |
06/22/2022 | Harpoon Therapeutics, Inc. | HARP | Grant | Director Stock Option (Right to Buy) | 10.2k | $2.01 | $20.4k | | 06/22/2022 |
06/22/2022 | Harpoon Therapeutics, Inc. | HARP | Grant | Director Stock Option (Right to Buy) | 32.1k | $2.01 | $64.6k | | 06/22/2022 |
06/15/2022 | Iterum Therapeutics plc | ITRM | Grant | Restricted Share Units | 237.8k | $0.01 | $2.4k | | 06/15/2022 |
06/02/2022 | Enliven Therapeutics, Inc. | IMRA | Grant | Stock Options (Right to Buy) | 8.5k | $1.07 | $9.1k | | 06/02/2022 |
04/21/2022 | Pyxis Oncology, Inc. | PYXS | Sale | Common Stock | 1.7M | $3.05 | $5.3M | See footnote | 04/21/2022 |
03/31/2022 | Pyxis Oncology, Inc. | PYXS | Grant | Common Stock | 66.8k | $0.00 | $0 | | 03/31/2022 |
10/13/2021 | Pyxis Oncology, Inc. | PYXS | Conversion | Series B Convertible Preferred Stock | 9.1M | $0.00 | $0 | See footnote | 10/13/2021 |
10/13/2021 | Pyxis Oncology, Inc. | PYXS | Purchase | Common Stock | 312.5k | $16.00 | $5M | See footnote | 10/13/2021 |
10/13/2021 | Pyxis Oncology, Inc. | PYXS | Conversion | Common Stock | 1.4M | $0.00 | $0 | See footnote | 10/13/2021 |
10/07/2021 | Pyxis Oncology, Inc. | PYXS | Grant | Stock Option (Right to buy) | 42.2k | $16.00 | $675.1k | | 10/07/2021 |
07/16/2021 | Enliven Therapeutics, Inc. | IMRA | Purchase | Common Stock | 1.3M | $6.00 | $8M | By entities affiliated with Arix Bioscience plc | 07/16/2021 |
06/29/2021 | Enliven Therapeutics, Inc. | IMRA | Grant | Stock Options (Right to Buy) | 7.7k | $8.12 | $62.8k | | 06/29/2021 |
06/23/2021 | Iterum Therapeutics plc | ITRM | Grant | Restricted Stock Units | 36.8k | $0.00 | $0 | | 06/23/2021 |
05/04/2021 | Harpoon Therapeutics, Inc. | HARP | Grant | Director Stock Option (Right to Buy) | 2.4k | $0.00 | $0 | | 05/04/2021 |
05/04/2021 | Harpoon Therapeutics, Inc. | HARP | Grant | Director Stock Option (Right to Buy) | 10.2k | $0.00 | $0 | | 05/04/2021 |
05/04/2021 | Harpoon Therapeutics, Inc. | HARP | Grant | Director Stock Option (Right to Buy) | 10.2k | $22.50 | $228.8k | | 05/04/2021 |
05/04/2021 | Harpoon Therapeutics, Inc. | HARP | Grant | Director Stock Option (Right to Buy) | 3k | $22.50 | $67.9k | | 05/04/2021 |
07/28/2020 | Iterum Therapeutics plc | ITRM | Other (disposition) | Ordinary Shares | 11.9k | $0.00 | $0 | | 07/28/2020 |
07/01/2020 | Iterum Therapeutics plc | ITRM | Exercise | Restricted Stock Units | 5.7k | $0.00 | $0 | | 07/01/2020 |
05/28/2020 | Harpoon Therapeutics, Inc. | HARP | Grant | Director Stock Option (Right to Buy) | 10.2k | $20.59 | $209.3k | | 05/28/2020 |
05/28/2020 | Harpoon Therapeutics, Inc. | HARP | Grant | Director Stock Option (Right to Buy) | 3k | $20.59 | $62.1k | | 05/28/2020 |
04/07/2020 | Iterum Therapeutics plc | ITRM | Other (disposition) | 6.500% Exchangeable Senior Subordinated Note due 2025 | 0 | $0.00 | $0 | By Arix Bioscience Holdings Ltd. | 04/07/2020 |
04/07/2020 | Iterum Therapeutics plc | ITRM | Other (disposition) | Ordinary Shares | 1.1M | $0.00 | $0 | By Arix Bioscience Holdings Ltd. | 04/07/2020 |
03/16/2020 | Enliven Therapeutics, Inc. | IMRA | Conversion | Common Stock | 1.4M | $0.00 | $0 | By entities affiliated with Arix Bioscience plc | 03/16/2020 |
03/16/2020 | Enliven Therapeutics, Inc. | IMRA | Purchase | Common Stock | 187.5k | $16.00 | $3M | By entities affiliated with Arix Bioscience plc | 03/16/2020 |
03/16/2020 | Enliven Therapeutics, Inc. | IMRA | Conversion | Series B Preferred Stock | 8.6M | $0.00 | $0 | By entities affiliated with Arix Bioscience plc | 03/16/2020 |
03/16/2020 | Enliven Therapeutics, Inc. | IMRA | Grant | Stock Option (right to buy) | 15.5k | $16.00 | $247.3k | | 03/16/2020 |
01/21/2020 | Iterum Therapeutics plc | ITRM | Grant | 6.500% Exchangeable Senior Subordinated Note due 2025 | 0 | $1,900,000.00 | $0 | By Arix Bioscience Holdings Ltd. | 01/21/2020 |
|